Foreign pharma trademark portfolios in Russia face unique IP risks — registration gaps, parallel imports, bad-faith threats. Make an enquiry.
Defending a Russian trademark portfolio in the pharmaceuticals sector requires attention to several Russia-specific rules that do not have direct equivalents in EU or US practice. The short answer for foreign in-house counsel is this: Rospatent registration in Russia remains mandatory regardless of international registrations held elsewhere, the pharmaceuticals sector carries an additional layer of state regulation that intersects directly with trademark scope, and bad-faith third-party applications are a live and documented risk — particularly for INN-adjacent marks.
Under Russian intellectual property legislation, trademark rights are territorial. A mark registered under the Madrid System receives Russian designation, but active monitoring and timely renewal at Rospatent are the practical foundation of any defensive strategy. In the pharmaceuticals sector, the interplay between trademark protection and the state registration of medicinal products means that the scope of a mark — and the evidence needed to enforce it — often turns on how the product is classified in the State Register of Medicines, not solely on the Nice Classification used at Rospatent. This intersection is a common source of dispute, and Russian courts have developed a substantial body of decisions on how these two regulatory systems interact.
In practice, foreign pharmaceutical companies defending a Russian trademark portfolio should monitor three risk areas: bad-faith applications by local competitors targeting marks similar to internationally recognised drug names; parallel import channels following Russia's introduction of permissive parallel import rules, which can affect both trademark exhaustion arguments and anti-counterfeiting strategy; and non-use cancellation actions, which may be brought after five years of non-use — a timeline that can catch foreign companies whose Russian market entry has been delayed by regulatory approval processes.
The recommended next step for any foreign company reviewing its Russian IP position is a portfolio audit covering registration status, use evidence, and sector-specific enforcement options before a dispute arises. For guidance on the procedural steps involved, see IP Enforcement at Vetrov & Partners and the related analysis at How Russian courts approach defending a Russian trademark portfolio.
To discuss your pharmaceutical trademark portfolio in Russia — make an enquiry: info@vetrovpartners.com |
— Elizaveta Razina Senior Lawyer, Practice Lead — IP Enforcement, Vetrov & Partners vetrovpartners.com/razina/
Elizaveta Razina leads the firm's intellectual property practice, representing foreign trademark owners in infringement proceedings before Russian state courts and the IP Court. She has been with the firm since 2012 and holds a degree from Novosibirsk State University (2013). She advises on anti-counterfeiting strategy and parallel import controls.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry